VivoSeq
Other

Patent Foramen Ovale

13

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Patent foramen ovale is an emerging landscape with 13 programs across 5 companies. The most active players are Bristol-Myers Squibb, Viatris Specialty LLC, Sanofi. 5 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

60/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2V

Viatris Specialty LLC

1 program

ApprovedSanofi logo

Sanofi

1 program

ApprovedGrifols Therapeutics LLC logo

Grifols Therapeutics LLC

1 program

ApprovedBayer logo

Bayer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

14

clinical trials

Unknown status4 · 29%
Completed3 · 21%
Active, not recruiting2 · 14%
Recruiting2 · 14%
Withdrawn2 · 14%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
Recruiting·TTaichung Veterans General Hospital·N/A·NCT07479147·400 enrolled
Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale
Recruiting·PPeking University Third Hospital·N/A·NCT06953622·330 enrolled
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05213104·186 enrolled
Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure
Active, not recruiting·—·N/A·NCT05907694·714 enrolled
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
Not yet recruiting·NNational University Hospital, Singapore·N/A·NCT06983795·1,000 enrolled
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00562289·664 enrolled
Patent Foramen Ovale in Cryptogenic Stroke Study
Completed·—·Phase 4·NCT00697151·630 enrolled
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
Completed·WW.L.Gore & Associates·N/A·NCT00738894·664 enrolled
Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation
Withdrawn·MMayo Clinic·N/A·NCT03232450
Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Withdrawn·MMayo Clinic·Phase 2·NCT02378623
PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism
Unknown status·FFoundation for Cardiovascular Research, Zurich·Phase 4·NCT00166257·414 enrolled
Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)
Unknown status·NNMT Medical·Phase 2/3·NCT00201461·900 enrolled
Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO)
Unknown status·—·Phase 4·NCT01550588·210 enrolled
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
Unknown status·—·Phase 4·NCT05546320·1,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)